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Background: Randomized controlled trials with a survival endpoint are the gold standard for clinical research, but
have failed to achieve cures for most advanced malignancies. The high costs of randomized clinical trials slow
progress (thereby causing avoidable loss of life) and increase health care costs.
Discussion: A malignancy may be caused by several different mutations. Therapies effective vs one mutation may
be discarded due to lack of statistical significance across the entire population. Conversely, expensive large
randomized trials may have sufficient statistical power to demonstrate benefit despite the therapy only working in
subgroups. Non-cost-effective therapy is then applied to all patients (including subgroups it cannot help).
Randomized trials comparing therapies with different mechanisms of action are misleading since they may
conclude the therapies are “equivalent” despite benefitting different subpopulations, or may erroneously conclude
that one therapy is superior simply because it targets a larger subpopulation. Furthermore, minor variances in
patient selection may determine study outcome, a therapy may be discarded as ineffective despite substantial
benefit in one subpopulation if harmful in another, randomized trials may more effectively detect therapies with
minor benefit in most patients vs marked benefit in subpopulations, and randomized trials in unselected patients
may erroneously conclude that “shot-gun” combinations are superior to single agents when sequential
administration of personalized single agents might work better and spare patients treatment with drugs that
cannot help them. We must identify predictive biomarkers early by comparing responding to progressing patients
in phase I-II trials. Enriching randomized trials for biomarker-positive patients can markedly reduce required patient
numbers and costs despite expensive screening for biomarker-positive patients. Available data support approval of
new drugs without randomized trials if they yield single-agent sustained responses in patients refractory to
standard therapies. Conversely, new approaches are needed to guide development of drug combinations since
both standard phase II approaches and phase II-III randomized trials have a high risk of misleading.
Summary: Traditional randomized clinical trials approaches are often inefficient, wasteful, and unreliable. New
clinical research paradigms are needed. The primary outcome of clinical research should be “Who (if anyone)
benefits?” rather than “Does the overall group benefit?”
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Unsustainable cost of our gold standard
Randomized controlled clinical trials (RCCTs) with sur-
vival endpoints are considered the gold standard of oncol-
ogy research since death is an unambiguous endpoint,
since longer survival is an important outcome, and since
randomization is regarded as the optimal method to con-
trol for confounding variables and biases. However, it now* Correspondence: dstewart@toh.on.ca
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distribution, and reproduction in any mediumcosts $800M-$2B to bring a new drug from discovery to
market, with gold-standard RCCTs being a major factor
driving costs [1]. The average price is $47,000 per patient
on phase III trials [2], with costs as high as $85,000 per
patient in some studies [3], and with unwieldy research
regulation driving much of the per-patient costs [4]. High
research costs slow progress, since far fewer ideas can be
tested with available resources, and delays in access to
effective therapies can result in unnecessary loss of huge
numbers of life-years [4]. Progress is further slowed byCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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patients.
There are currently an estimated 800 new anticancer
agents in clinical development [5], making it impossible
to test most new drugs in more than a minority of situa-
tions where they might be useful [6]. While some of the
800 drugs in development have similar mechanisms of
action, we cannot necessarily rely on testing with one
member of a drug class to tell us what will happen with
other members. For example, the BRAF inhibitor
sorafenib is inactive against malignant melanoma with
BRAF V600E mutations [7], while another BRAF inhibi-
tor, vemurafenib, is highly active [8]. Consequently,
requiring RCCTs for drug approval in each clinical situ-
ation means we are certain to miss numerous important
new therapeutic opportunities at the same time that we
are driving up health care costs. Current drug develop-
ment paradigms are unacceptably wasteful and inefficient.
The unfulfilled promise
The historical goal of RCCTs was step-wise incremental
survival improvements that would initially convert incur-
ability into occasional cures, followed ultimately by high
cure rates, as happened with childhood leukemia [9].
RCCTs have contributed to improved adjuvant therapy
and to modest prolongation of survival in the advanced
disease setting for many malignancies. However, most
cancers remain incurable when metastatic despite decades
of successive minor incremental advances from RCCTs
[10], and the impact of most new drugs has been small,
with a median survival gain of only 2.19 months for drugs
approved by the US FDA over the past 10 years [11]. The
authors (neither of whom is a statistician) feel that faulty
RCCT goals, endpoints, patient selection, and interpret-
ation by clinicians, regulators and statisticians have played
a role in slowing progress by facilitating and encouraging
the pursuit of small advances, by prompting rejection of
therapies that benefit subpopulations and by diverting
resources away from other strategies [10].
Fool’s gold
Early prospectors named ferrous sulfate “fool’s gold”. Its
yellow color misled many into believing they had discov-
ered great riches. We suggest that RCCTs are often fool’s
gold- potentially deceptive and of limited value. Unques-
tionably, faulty conclusions can be drawn if one ignores
the potential biases and errors that RCCTs are intended
to prevent, but equally faulty conclusions can be drawn
if the design and interpretation of RCCTs fails to
adequately account for clinical and biological realities.
Our goals
In this manuscript we will illustrate some of the ways in
which RCCTs in unselected cancer patients may lead toerroneous conclusions. We will discuss why identifica-
tion of predictive biomarkers early in the course of
clinical drug development is very important, why use of
response as the clinical endpoint is more efficient for
biomarker discovery than is use of overall survival, and
how early development of predictive biomarkers can
speed drug development and markedly cut drug devel-
opment costs. We will also discuss why traditional ways
of doing phase II trials may no longer be appropriate,
why drugs that lead to high response rates in defined
populations should be approved without requirement for
RCCTs, and why we need to change the way we assess
drug combinations.
Discussion
Impact of molecularly distinct subgroups
Common cancers may be common since many mutations
can cause them, and the probability of a particular therapy
being beneficial may be strongly influenced by the pres-
ence of specific mutations [12]. Traditional RCCTs in un-
selected patients attempt to “overwhelm” molecular and
clinical heterogeneity through randomization processes
that are intended to achieve a balance between study arms
with respect to factors that may impact outcome. How-
ever, this approach carries a substantial risk of generating
erroneous conclusions unless most patients express the
target of interest.
To illustrate this, we used GraphPad Prism 5 (GraphPad
Software Inc, San Diego, CA) to perform limited simula-
tions to generate examples of different ways in which
erroneous conclusions can be drawn, with the nature of
the error varying with the number of patients in the study,
the size of a subpopulation with a target required for drug
efficacy and the degree of benefit the drug conferred to
patients with vs without the target [4]. We used the actual
survival in 334 non-small lung cancer (NSCLC) patients
as a “control” arm and a simulated group of 334 patients
as the “experimental” arm. To provide a more accurate es-
timate of the probability of arriving at each type of errone-
ous conclusion with different sets of circumstances would
have required several thousands of simulations, but that
was not our objective. The probability of encountering
each type of problem we address would differ if the simu-
lations were run thousands of times using different data
sets, but this would not alter the fact that there is a risk of
each type of problem occurring if RCCTs are done in un-
selected patients, with the size of the risk varying inversely
with the size of the subpopulation that might most benefit
from the therapy.
RCCTs may lead to loss of useful therapies
It is now widely recognized that effective therapies may
be missed by RCCTs in unselected patients if the drug is
only active in subpopulations. Various trial strategies
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illustrate this problem, if we assumed that a required
target was present in every 10th patient (the approximate
frequency of epidermal growth factor receptor [EGFR]
mutations in Caucasians with NSCLC) and that therapy
quintupled survival in those with target (in keeping with
progression-free survival [PFS] gains when erlotinib is
used as post-chemotherapy maintenance in EGFR-mutant
NSCLC [20]), but was ineffective in those without target,
the simulated “study” in unselected patients failed to
achieve statistical significance (hazard ratio [HR]=0.85,
p=0.16), and a new therapy tested in this way would not
gain regulatory approval [4]. Since it costs on average
$47,000 per patient on phase III trials [2], this study would
cost $31,400,000, squander research resources, expose
90% of patients in the treatment arm to therapy incapable
of helping them, and lead to potential loss of a “treasure”
that is highly effective in subpopulations with target.
Despite the negative statistical outcome, investigators
might conclude that the therapy was of value since
survival curves diverged and 10% of patients responded.
However, our past experiences tell us that many regula-
tors, statisticians and clinicians would argue otherwise,
and access to the drug would probably be at least sub-
stantially delayed, and there would be a high risk that
the drug would be abandoned.
A case in point is gefitinib in NSCLC. Despite being of
marked benefit in a subpopulation who experienced dra-
matic tumor regression, the survival gain was not statis-
tically significant (p=0.09) in unselected patients [21],
gefitinib was discarded for a period of time in North
America and Europe, and the authors witnessed debates
around why the related drug erlotinib was “effective”
while RCCTs had “proven” gefitinib to be “ineffective”.
While some investigators and statisticians would argue
that this would be an incorrect conclusion, and would
point out that the gefitinib [21] and erlotinib [22]
survival curves are in fact extremely similar, one might
well be concerned that a negative RCCT would intro-
duce a strong bias against a drug, irrespective of issues
with study design, and that this would hamper further
study of the drug. A delay in approval of an agent with
even modest activity can cause substantial loss of poten-
tial years of life [4]. While there is a growing appreci-
ation of the risk of loss of valuable agents through
RCCTs in unselected patients, these trials continue to be
done.
Large RCCTs may spawn low selectivity and poor cost-
effectiveness
If we tripled patient numbers to 2,000 (current cost,
$94,000,000 at $47,000 per patient) then survival gain
and HR remained unchanged from the smaller simulated
study, but increased statistical power yielded a p-value of0.03 [4]. If the therapy only doubled survival in those
with target, then more than 5300 unselected patients
were required for significance (p=0.047, current cost
$249,000,000) [4]. Since neither of these larger studies
identified that only 10% of patients benefited, this expen-
sive, potentially toxic therapy might well become the
standard of care for the entire population, but would not
help 90% of patients. With an α-error of 0.05, one study
out of 20 of ineffective agents could be positive despite
lack of any benefit.
The larger the RCCT, the smaller the benefit poten-
tially detected and the poorer the cost-effectiveness.
While this is an issue in oncology, it is an even bigger
issue in other areas of medicine such as cardiology (we
have referenced just a few of the very numerous exam-
ples) [23-26], where it is commonplace to detect statisti-
cally significant but extremely small absolute gains in
survival by enrolling thousands of patients on studies,
with a high proportion of studies being negative, despite
the very large patient numbers enrolled.
Ocana et al. proposed that to reduce the risk of
accepting therapies with only minimal benefit, a study
should only be declared positive if the difference
between the experimental arm and the control arm met
a pre-specified size, in addition to the p-value being
significant [27]. While this might reduce the risk of
widely applying a therapy that only worked in a subpop-
ulation, it would increase the risk of discarding a therapy
that was of high value, but only in a subpopulation.
Comparing therapies hitting different targets
RCCTs are often designed to compare efficacy of two
therapies. When we compared one simulated therapy
that quintupled survival in every 10th patient starting
with patient number 10 to another that quintupled
survival in every 10th patient starting with patient 11,
the statistical conclusion was that these therapies were
equivalent (p=0.89) (Figure 1). However, this statistical
conclusion is erroneous since the therapies are not
equivalent: they are benefiting different subpopulations.
As a recent example, the NSCLC INTEREST study
comparing gefitinib to docetaxel concluded that the two
therapies were equivalent [28], but gefitinib gave a
higher response rate and longer PFS than docetaxel in
patients with EGFR mutations, while there was a trend
towards docetaxel giving more responses and longer PFS
in EGFR-wild-type patients [29]. It might have been rea-
sonable to conduct a trial to assess the hypothesis that
gefitinib would be the better drug in EGFR-mutant
patients and that docetaxel would be the better drug in
EGFR-wild-type patients, but it was not rational to
conduct a study assessing whether the two drugs were
equivalent. One could only conclude that they were
equivalent by confining oneself to the statistical outcome
Figure 1 Comparison of therapies hitting different simulated
targets: Comparisons of a simulated therapy that quintupled
survival in every 10th patient starting with patient number 10
to another that quintupled survival in every 10th patient
starting with patient number 11 would erroneously conclude
that the two therapies are equivalent (p=0.89), despite them
being of benefit in completely different subpopulations.
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different ways.
Furthermore, if drug A hits a target present in 40% of
patients while drug B hits a target present in only 20%,
the statistical conclusion will be that drug A is the better
drug [4,30]. Drug A is not better. It just hits a more
common target. For the smaller subpopulation, drug B is
the more effective therapy. If this goes unrecognized,
then drugs that are important in smaller subpopulations
will be discarded, the standard of care will be drug A, all
patients will be treated with drug A despite it being
incapable of helping the 60% who lack required target,
and there will be no further advances if no target isFigure 2 Impact of minor changes in proportion of patients with targ
patients with a particular target, the 668-patient simulated study was
(HR=0.81, p=0.06) but was positive if the target was present in just 1
variations in study patient populations can determine whether a trial will bmore common than drug A target. It is illogical to use
RRCTs in unselected patients to compare two agents
hitting different targets.Minor variability in patient selection may sway outcomes
Small changes in patient characteristics may change
study conclusions. If survival was quintupled in patients
with a target present in 15% of patients, the therapy
would be at risk of being discarded in our 668 patient
simulated study since the study would not achieve
statistical significance (HR=0.81, p=0.06), but would be
accepted as effective if the target were present in just 11
more patients (16.7%) (HR=0.79, p=0.04) (Figure 2). For
example, since both EGFR mutations [31] and EML4/
ALK fusions [32] are more common in NSCLC non-
smokers than in smokers, success of RCCTs of EGFR or
EML4/ALK inhibitors in unselected patients could
depend on minor variability in smoking incidence in the
neighborhoods from which patients were recruited.Benefit in one subpopulation, harm in another
RCCTs in unselected patients may also discard a therapy
that is beneficial in one subpopulation if it is harmful in
another. For example, NSCLC RCCTs adding erlotinib
to chemotherapy concluded that erlotinib had little
effect [33]. However, subsequent molecular assessments
suggested that progression-free survival (PFS) (Figure 3)
and response were increased by erlotinib in the 13% of
patients with EGFR mutations but were significantly
decreased by erlotinib in the 21% of patients with
KRAS mutations [34]. Similarly, the anti-EGFR antibody
cetuximab was associated with significant worsening of
outcome when added to standard therapy in the treatmentet in simulated trials: If a new therapy quintupled survival in
negative if the target was present in 15% of patients
1 more patients (16.7%) (HR=0.79, p=0.04). Hence, very minor
e negative vs positive.
Figure 3 Impact of benefit of erlotinib in one subpopulation vs
harm in another: Despite substantial benefit in one
subpopulation, a randomized trial may conclude that an agent
is ineffective if it causes harm in a different subpopulation.
Erlotinib vs placebo were added to chemotherapy in NSCLC, [33] and
the curves overlapped suggesting no impact of erlotinib (two center
curves, redrawn from Herbst et al. [33]). However, on molecular
assessment, erlotinib was associated with potential benefit in the 13%
of patients with an EGFR mutation (p=0.09), but was associated with
harm in the 21% of patients with KRAS mutations (p=0.03) (curves
resynthesized using component parts from Eberhard et al. [34]).
Figure 4 Therapy giving minor benefit in all patients achieved
significance in simulated trial: In a 668 patient simulated study,
a therapy that increased survival by 33% in all patients was
judged to be effective (HR=0.80, p=0.03) (survival curves
presented here), while a therapy that quintupled survival in
10% of the patients was judged ineffective (HR=0.85, p=0.16,
see Figure 1 from Stewart, Whitney and Kurzrock [4]).
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may improve outcome in KRAS-wild-type patients [36].
Types of gains detected by RCCTs
RCCTs in unselected patients may be less effective at
detecting large gains in subpopulations than at detecting
small gains in the overall population [4]. As noted above,
our 668-patient simulated trial of a drug that quintupled
survival in 10% of patients (e.g., increasing median sur-
vival from 2 months to 10 months) would fail to achieve
statistical significance, while a simulated trial of therapy
that increased survival in all patients by 33% (e.g., from a
median of 2 to 2.7 months, a gain of 21 days, similar to
the statistically significant but clinically minute 11-day
median survival gain seen when erlotinib was added to
chemotherapy in the treatment of metastatic pancreatic
cancer [37]) did achieve significance (HR=0.80, p=0.03,
Figure 4). Despite these different statistical conclusions,
the life-years gained across a total population of 100
patients might be higher with the quintupling of survival
in a 10% subpopulation than with an increase in survival
of 33% in each member (6.7 vs 5.8 life-years in our simu-
lated examples). Overall, conclusions reached by RCCTs
in unselected patients may be appropriate if the therapy
hits a target present in most patients, but will be prob-
lematic for drugs hitting less common targets.
False negatives and positives due to unrelated factors
While survival has the advantage that it is a very precise
endpoint, it has the disadvantage that unrelated factors
may impact it to a greater extent than they impact
response or PFS, and a therapy may fail to be associatedwith a survival advantage for reasons unrelated to ther-
apy efficacy [38]. Specifically, the probability of detecting
a significant survival benefit can be blunted by the
impact of major comorbidities, cross-over to the study
agent, long post-progression survival for any reason [39],
or palliative care (which can prolong survival [40]). Con-
versely, some therapies may correlate with survival for
reasons that have nothing to do with their anticancer
effects. For example, adjuvant BCG prolonged survival of
colorectal cancer patients by reducing deaths from heart
disease without having any apparent impact on the
patients’ cancers [41]. In any trial with a survival endpoint,
detailed information should be collected following discon-
tinuation of study therapy to help better assess the impact
of subsequent therapy and of unrelated events.
Randomized discontinuation designs
It has been suggested that for cytostatic agents, assessing
further time to progression after randomizing stable pa-
tients to continue vs stop a therapy could provide proof
of benefit. For example, this approach demonstrated
potential benefit of sorafenib in metastatic renal cell
carcinoma [42]. However, waterfall plots from this study
suggest that approximately 70% of treated patients had
at least some degree of tumor shrinkage, and it is debat-
able whether the addition of a randomized discontinu-
ation approach added much value. This approach also
requires relatively large numbers of patients, and it has
been questioned whether it is ethical to withdraw a ther-
apy that is controlling a patient’s cancer [43]. Further-
more, while this approach is intended to assess the
benefit of stable disease, stable disease (unlike response)
does not correlate with PFS or survival for either
targeted agents or chemotherapy [11,44], and we agree
Stewart and Kurzrock BMC Cancer 2013, 13:193 Page 6 of 19
http://www.biomedcentral.com/1471-2407/13/193[10] with Fojo and Noonan [11] that aiming for stable
disease is aiming too low.
Chemotherapy
Publications have stressed the importance of new clinical
trial designs for targeted agents [13-19]. However, new
trial designs might be as important for chemotherapy.
For most adult malignancies, only a subpopulation of
patients responds to most chemotherapy single agents.
Differential sensitivity is potentially due to discoverable
molecular differences, and there are many factors that
influence tumor sensitivity [45,46]. Defining the factors
that are important clinically could convert chemotherapy
into targeted therapy.
RCCTs to discover predictive biomarkers
A variety of strategies have been described to discover or
validate predictive biomarkers [47-50]. In some RCCTs,
post-hoc analysis (using survival as the clinical endpoint)
has been done to identify biomarkers predicting drug
benefit [51,52], and we have heard it argued that their
use in discovery of important biomarkers is one reason
why RCCTs are of value. However, while RCCTs may be
used in a variety of ways to validate biomarkers [50],
RCCT post-hoc analyses have been at best only modestly
successful as a strategy to discover clinically important
biomarkers that can permit rational patient selection.
Various adaptive designs have also been proposed.
For example, the probability of a patient with a given
biomarker being randomized to receive an agent may
increase if earlier marker-positive patients benefited
from the agent [13]. The major issue with this approach
is that only a relatively small number of biomarkers can
be assessed. While adaptive designs may be useful in
validating predictive biomarkers [50], they have not yet
proven to be an efficient way of discovering previously
unappreciated biomarkers. An adaptive signature ap-
proach, wherein outcomes with a therapy vs control
group are compared in different biomarker groups [16],
may possibly prove more useful, although this remains
to be determined.
Identification of markers correlating with tumor
regression in phase I-II trials
There are several potential advantages to using durable
tumor regression in phase I, II and III trials (and not sur-
vival) as the outcome variable in discovering predictive
biomarkers [4,50]. Since tumors do not usually shrink
spontaneously, tumor shrinkage generally indicates drug
effect, one can tell which individual patients benefitted,
and you only require a few weeks or months of patient
follow-up time to determine response. As noted above,
survival has the advantage of being a more precise end-
point than response, but it has the distinct disadvantagesof being impacted by a variety of factors unrelated to ther-
apy efficacy, one cannot tell which patients actually bene-
fited from therapy, and it requires several months or years
of patient follow-up time. Generally, far larger patient num-
bers are needed to detect an association of a biomarker
with survival than with response. For example, benefits of
cetuximab and panitumumab in colorectal cancer and ben-
efits of the EGFR tyrosine kinase inhibitors (TKIs) erlotinib
and gefitinib in NSCLC are respectively associated with
presence vs absence of KRAS and EGFR mutations. Across
a range of colorectal cancer and NSCLC studies, p-value
for association of response with mutation status was usually
more significant than association of overall survival with
mutation status (Table 1) [35,36,52-70], in keeping with in-
creased statistical power with a response endpoint. PFS also
generally did better than overall survival, and was almost as
good as response (Table 1).
Furthermore, since survival is impacted by both pre-
dictive factors (linked to therapy efficacy) and prognostic
factors (linked to tumor aggressiveness, irrespective of
therapy), RCCTs comparing patients with vs without a
factor in a therapy arm vs a control arm are needed to
differentiate predictive from prognostic factors if using a
survival endpoint [71], and this further increases the
number of patients required to discover or validate a
predictive biomarker. Response is likely to be much less
influenced by prognostic factors than is survival, and
hence does not require RCCTs to differentiate predictive
factors from prognostic factors.
For some agents, assessment of tumors from patients
with responses in phase I or II trials led to the discovery
of important, previously-unappreciated biomarkers (e.g.,
EGFR activating mutations for erlotinib and gefitinib in
NSCLC [72,73], EML4/ALK fusions for crizotinib in
NSCLC [74], and KRAS mutation status for cetuximab
in colorectal cancer [53]). Other response observations
have suggested potentially important biomarkers that are
currently being assessed further (e.g., DDR2 mutations
[75] and inactivating BRAF mutations [76] for dasatinib
in NSCLC). Phase I and II trials with relatively small
numbers of patients have also supported the importance
of other biomarkers that were a priori hypothesized to be
important (e.g., estrogen receptors for tamoxifen in breast
cancer [77], Her-2/neu overexpression for trastuzumab in
breast cancer [78], BCR/ABL fusion genes for imatinib in
chronic myelogenous leukemia [79], c-KIT mutations for
imatinib in gastrointestinal stromal tumors [80], BRAF
v600E mutations for selected BRAF inhibitors in malig-
nant melanoma [81], and PD-L1 expression for an anti-
PD-1 antibody [82]). Furthermore, patient outcomes were
substantially better in phase I trials where patients were
selected based on putative biomarkers [83].
Currently available data for selected biomarkers suggest
that a high proportion of biomarker-positive patients may
Table 1 Differences in p values when using response vs






P values for differences in outcome for KRAS wild type vs KRAS mutant
colorectal cancer patients treated with single agent monoclonal
antibody:
Panitumumab [52] 427 <0.0001b <0.0001 >0.05
Cetuximab [53] 30 0.0003 NRc 0.016
Cetuximab [54] 108 0.000001 0.074 0.020
P values for differences in outcome for KRAS wild type vs KRAS mutant
colorectal cancer patients treated with combined monoclonal antibody
and chemotherapy:
Cetuximab [55] 110 0.0024 0.0009 NR
Cetuximab [56] 69 0.021 0.021 0.15
Cetuximab [35] 256 0.03 0.04 0.06
Cetuximab [57] 540 0.03 0.07 0.44
Cetuximab [58] 88 0.024 0.003 0.0004
Cetuximab [59] 48 0.144 0.048 NR
Cetuximab [36] 315 <0.001 <0.001 0.12
Cetuximab [60] 67 0.07 0.14 0.047
Cetuximab [61] 1,063 0.0005 0.0028 0.0463
Cetuximab [62] 58 0.027 0.024 0.107
P values for differences in outcome for EGFR wild type vs EGFR mutant
NSCLC patients treated with single agent tyrosine kinase inhibitor:
Gefitinib or erlotinib [63] 223 <0.0001b <0.0001 0.002
Gefitinib [64] 57 0.002 NR 0.11
Gefitinib [65] 100 0.0017 NR 0.0135
Gefitinib [66] 68 0.0001 NR 0.001
Gefitinib [67] 66 <0.0001 <0.0001 0.0001
Gefitinib [68] 83 0.001 0.002 0.02
Erlotinib [69] 36 0.006 NR 0.045
Erlotinib [70] 116 0.035 NR 0.47
a. Comparison of outcome in mutant vs wild type or p value for interaction
between treatment arm on a comparative study and mutation status.
b. Calculated from published data using Fisher’s exact test.
c. NR = not reported.
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achieve a RECIST response may nevertheless have meas-
urable tumor regression. We manually measured available
waterfall plots to estimate the proportions of patients with
tumor shrinkage of >30%, >10% and >0% for erlotinib and
gefitinib in EGFR-mutant NSCLC patients [63,84-89], for
crizotinib in NSCLC patients with EML4/ALK fusion
genes [90], and for vemurafenib in malignant melanoma
patients with BRAF V600E mutations [8]. We found that
50-84% of biomarker-positive patients had >30% reduc-
tion in tumor diameter, 80-95% had >10% reduction, and
90-100% had at least some degree of measurable reduc-
tion in tumor size (Table 2). Conversely, on placebo orbest supportive care (BSC) arms of other trials (Table 3),
RECIST objective responses were uncommon (median,
0%, range, 0-4%) [21,22,52,91-112], and the proportion
of patients with measured reduction in tumor diameter
of >10% was low (median, 6.6% of patients, range 1-9%,
as estimated from manual measurements of available
waterfall plots) [52,98-100,103,107,112]. The low pro-
portion of patients who were judged to have tumor
regression of >10% with placebo or BSC is in keeping
with the observation that on repeat scans done 15
minutes apart in 30 patients with lung lesions, there
was a decrease in size of >10% in only 7.8% of patients
with repeat measurement, and no patient had a de-
crease of greater than 25% [113].
Hence, where it would be helpful to increase statistical
power, it may be appropriate to use proportion of patients
with >10% tumor regression to compare biomarker-
positive to biomarker-negative patients when assessing the
biomarker as a potential predictive factor. In addition, this
type of approach might help estimate the proportion of
patients who have an important undiscovered predictive
biomarker. For example, in EGFR-wild type NSCLCs,
0-10% of patients (median, 8%) experience a >30% reduc-
tion in tumor diameter with erlotinib or gefitinib, and 12-
38% (median, 22%) experience a >10% reduction in tumor
diameter (Table 2) [63,84,85,88,89]. If we assume based on
the above observations that tumor regression >30% usu-
ally (but not always) indicates drug efficacy rather than
measurement error, that most patients with an important
biomarker who do not achieve partial remission will
nevertheless have some degree of tumor shrinkage, and
that approximately 5-10% of the time a measured tumor
regression of >10% will be due to measurement error
rather than being due to drug benefit, then we might esti-
mate that approximately 10-15% of EGFR-wild type
NSCLCs have a currently undefined sensitizing target that
could help explain apparent benefit of EGFR TKIs in
patients from groups that ordinarily do not respond to
these agents [114].
Conversely, of patients treated with panitumumab for
KRAS wild-type colorectal cancer, 17% achieved partial
remissions by RECIST criteria [52], 25% had tumor
regression of >30% (estimated from measurement of
waterfall plots) and 50% had tumor regression >10%.
Less than 1% of KRAS-mutant tumors shrank by >10%
(Table 2) [52]. This suggests that the still-unrecognized
“true target” for panitumumab (and cetuximab) is
present in 30-40% of KRAS wild-type colorectal cancers,
and in almost no KRAS-mutant colorectal cancers. It
appears that this hypothetical “true target” is also gener-
ally absent in tumors with BRAF mutations [115] or
PIK3CA mutations [116]. Overall, we have been less
successful at finding targets associated with a high prob-
ability of benefit from monoclonal antibodies than with




Biomarker % Biomarker-positive patients with tumor
shrinkagea














Panitumumab [52] Colorectal KRAS wild type 57% 50% 25% 4% 1% 0%
Erlotinib [84] NSCLC EGFR mutant 100% 83% 72% 28% 12% 8%
Erlotinib [85] NSCLC EGFR mutant 100% 83% 50% 31% 17% 3%
Erlotinib [86] NSCLC EGFR mutant 90% 88% 76%
Erlotinib [87] NSCLC EGFR mutant 100% 80% 70%
Gefitinib [88] NSCLC EGFR mutant 95% 95% 63% 72% 38% 10%
Gefitinib [89] NSCLC EGFR mutant 91% 82% 55% 67% 33% 0%
Erlotinib or
gefitinib [63]
NSCLC EGFR mutant 97% 91% 84% 45% 22% 9%
Crizotinib [90] NSCLC EML4/ALK fusion 94% 88% 69%
Vemurafenib [8] Melanoma BRAF V600E 96% 93% 76%
a. Calculated from manual measurement of available waterfall plots.
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because there have been insufficient molecular assess-
ments comparing patients with vs without tumor regres-
sion on single agent therapy with monoclonal antibodies,
although it remains possible that there are biological rea-
sons instead.
Cytostatic agents
It has been argued that a response endpoint would not
be informative with cytostatic agents since cytostatic
agents might confer benefit without inducing tumor
shrinkage [42]. However, a high proportion of targeted
agents that were initially anticipated to be cytostatic can
induce tumor shrinkage, including antiangiogenic agents
such as bevacizumab [117-122]. Hence, tumor shrinkage
could also potentially be a valid endpoint for biomarker
identification for purportedly cytostatic agents. On the
other hand, response may be somewhat less reliable with
immunotherapeutic approaches since in some instances,
there may be delayed tumor shrinkage, with or without a
period of continued tumor growth prior to onset of
sustained tumor shrinkage [82,123], or there may be pro-
longation of survival without response or improvement in
PFS [124].
Continuously variable and graded biomarkers vs
dichotomous biomarkers
In searching for useful biomarkers, dichotomous (present
vs absent) factors (e.g., gene mutation, amplification, dele-
tion or expression) may be easier to use than continuously
variable or graded markers (e.g., degree of gene or protein
expression). Continuously variable markers may be chal-
lenging due to measurement variability, time-dependent
expression fluctuations and biologically irrational use ofcut-points to dichotomize patients into low vs high benefit
groups, thereby classifying 51st percentile patients as dif-
ferent from 49th percentile patients but equivalent to 99th
percentile patients. There are few examples where
continuous variables have proven helpful clinically in
predicting benefit in individual patients unless the cut
point is placed at the extreme of almost no expression vs
any expression. For example, breast cancers with just 1-10%
of cells that are positive for estrogen receptors respond
far better to tamoxifen than do estrogen-receptor-negative
cancers and respond almost as well as highly positive
cancers [125]. Conversely, very high EGFR expression by
immunohistochemistry (IHC) may predict NSCLC benefit
from cetuximab [126], although this requires further con-
firmation. While very high Her-2/neu expression by IHC
appeared to predict trastuzumab benefit in some studies
[78,127,128], other authors have concluded that IHC is
not as reliable as FISH assessment of gene amplification
(any vs none) in predicting efficacy [129].
We would anticipate that continuous variables would
be most likely to be useful if there is a nonlinear rela-
tionship between expression and benefit (as noted above
for estrogen receptors), such that a true benefit thresh-
old can be identified. If the relationship between benefit
and marker expression is linear, then using cut points
could successfully validate that the marker was signifi-
cantly associated with outcome, but it would be less useful
as a guideline for making therapeutic choices. With linear
relationships, instead of using cut points, we should con-
sider models that enable estimation of a predicted patient-
specific probability or degree of benefit, analogous to the
approach used by Oncotype Dx to assign a specific
prognostic score and probability of benefit from adjuvant
chemotherapy to patients with resected breast cancer [130].
Table 3 Response rates and proportion of patients with
measured tumor shrinkage >10% in single agent placebo
or best supportive care arms of randomized trials
Tumor type RECIST
response %
% of patients with
measurable tumor
shrinkage >10%a
NSCLC [21] 1 NAb
NSCLC [22] <1 NA
NSCLC [91] 0.7 NA
NSCLC [92] 1 NA
Colorectal [52] 0 1
Colorectal [93] 0 NA
Colorectal [94] 0 NA
Renal cell [95] 2 NA
Renal cell [96] 0 NA
Renal cell [97] 3 NA
Renal cell [98] 0 4
Renal cell [99] 0 5.5
Hepatocellular [100] 0 9
Hepatocellular [101] 3 NA
Hepatocellular [102] 1.3 NA
Head and neck cancer [103] 0 7
Head and neck cancer [104] 1 NA
Head and neck cancer [105] 3 NA
Transitional cell [106] 0 NA
Pancreatic neuroendocrine [107] 0 7
Pancreatic neuroendocrine [112] 2 6.6
Prostate [108] 4 NA
Sarcoma [109] 0 NA
Medullary thyroid [110] 1 NA
Mesothelioma [111] 1.7 NA
a. Calculated by manual measurement of published waterfall plots.
b. NA = not available.
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While doing repeat biopsies to assess biomarkers is feas-
ible in patients with metastatic disease [131], the benefit
derived may vary with the patient’s situation. Contrary
to the findings of Bai et al. that tumor EGFR mutation
status changed after chemotherapy [132], the experience
with several biomarkers to date (including with EGFR
mutation status) suggests that formalin-fixed paraffin-
embedded (FFPE) archival tissues from initial diagnostic
biopsies may be a very adequate source of tissue for bio-
marker assessment, even if the patient has undergone
chemotherapy between tissue acquisition and adminis-
tration of the targeted therapy [53,72-74,77,78,80,81].
On the other hand, if the patient has undergone
targeted therapy and has responded to it, the character-
istics of the residual cancer at the time of progression
may be substantially different from the earlier diagnosticbiopsy since the targeted therapy may have suppressed
sensitive clones that made up the bulk of the tumor at
diagnosis, and may have permitted outgrowth of resist-
ant sub clones that may have made up an undetectably
small proportion of the cells in the original tumor
biopsy. An example is the selection of resistant T790M-
positive cells by treatment of EGFR-mutant NSCLC with
EGFR TKIs [133]. Hence, for assessment of tumor char-
acteristics in residual or recurrent cancers after initially
successful treatment with targeted agents, early experi-
ence suggests that fresh biopsies may be required.
In addition, while archival FFPE tissues may be quite
suitable for assessment of gene mutations and amplifica-
tion, tissue processing and fixing methods may reduce
accuracy of IHC assessments for at least some bio-
markers [129], raising the possibility that carefully
processed repeat biopsies may be required if therapy is
being directed by IHC assessments.
In obtaining fresh biopsies, core biopsies show tissue
architecture but fine needle aspirates (FNAs) have the
advantage that specimens consist mainly of tumor cells
with little stroma since tumor cells are less cohesive and
more easily aspirated than stromal cells [134]; hence,
laser-capture microdissection is unnecessary with FNAs
to obtain a relatively pure tumor cell population, and
FNAs work well for tumor molecular assessment pro-
vided fixation is with formalin (yielding FFPE cell blocks)
rather than with alcohol. FNAs are easier to obtain than
core biopsies for tumors in some locations (e.g., with
ultrasound-guided endobronchial sampling of medias-
tinal lymph nodes).
Patient selection using biomarkers correlating with
response can reduce costs
The extent to which selecting patients based on a bio-
marker may improve efficiency of phase III trials will
depend on the extent to which the treatment benefits
different patient subpopulations, the proportion of the
population that belong to sensitive subpopulations and
the reliability of the assay [135]. If the subpopulation
possessing a target that is required for benefit is rela-
tively small and if the therapy is of limited benefit in
those without the target, then the number of patients
required for a phase III trial to demonstrate benefit of a
new therapy may be much smaller if one selects for the
target than if one uses unselected patients [50]. In keep-
ing with this, in our simulations, if we had first identified
the important target based on differences between a few
responders and non-responders in phase I-II trials and if
we then confined RCCTs to patients with this target,
only 16 patients would have been needed in a phase III
trial with a survival endpoint to confirm drug efficacy in
the extreme example of drug quintupling survival in
those with target (HR=0.2, p<0.02), while 84 patients
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those with target (HR=0.5, p<0.04) [4].
If it cost $10,000 per patient to screen 160 patients to
find the 16 needed where drug quintuples survival, then
the trial (including screening) would cost $2,350,000,
while it would cost $12,348,000 to screen 840 patients
and study 84 in the situation where drug doubled
survival. In both cases, RCCT patient numbers would be
reduced by >98% and trial costs by >94% compared to
those required to detect benefit using unselected
patients. Post-marketing drug utilization would be
reduced by 90%. Hence, even large upfront investments
in defining targets linked to response in early trials could
prove highly cost-effective. It is stressed that while these
examples are illustrative only, and that while actual
reduction in costs and resource utilization in individual
situations might be much less than suggested by our
examples, they may nevertheless be substantial.
Design of phase II trials
By the Simon 2-stage design [136] and similar
approaches, 14–15 patients are typically entered on the
first stage of a phase II trial. If responses are seen, then
the phase II trial is expanded, while if no responses are
seen, the study is stopped since there will then be less
than a 5% probability that the true response rate will be
20% or higher. While RCCTs in unselected patients are
problematic in the era of targeted therapies, the Simon
2-stage phase II trial design may also no longer be
appropriate in many situations. Since uncommon tumors
may be uncommon as a consequence of having only a
small number of potential driving mutations [12], and
since a high proportion of patients with a relevant muta-
tion may respond to a targeted agent (as noted above),
then relatively small phase II trials may be reasonable with
uncommon malignancies.
However, this approach is probably not appropriate for
common malignancies, where there may be a large num-
ber of different driving mutations, and entering 14–15
unselected patients with common malignancies on a
phase II trial should not be used as a basis for rejecting
the agent. The options need to include either much
larger phase II trials, with adjusted early stopping rules
and with tissue acquisition on all patients to enable mo-
lecular characterization of any responding patients, or
else the phase II trials need to be limited to patients
who have already been characterized, with enrichment
for potential targets. However, the factor(s) that we think
will be important for drug activity based on preclinical
models may end up not being the ideal or relevant
target, as was the case with EGFR IHC expression for
EGFR TKIs in NSCLC and for cetuximab in colorectal
cancer [137]. Furthermore, there may be very important
targets that are not identified by preclinical data, such asEML4/ALK fusions in crizotinib-treated NSCLC [74],
and a drug may be effective against more than one
target. For example, in addition to being effective against
EML4/ALK fusions, crizotinib may also be effective
against NSCLCs with ROS1 fusion genes and with c-Met
amplification [138,139]. Hence, our phase II catchment
strategies have to be sufficiently broad to compensate
for the fact that we may potentially get it wrong,
although the preclinical data did correctly predict activ-
ity in several instances [77-82].
Since presence of a target may be associated with a
very high probability of tumor regression, one option
would be to undertake large phase II trials (with tissue
acquisition), but to stop accrual of patients with specific
mutations if none of the first 3–4 patients had tumor
regression >10%, while accrual would be continued for
other mutations. It would be important to consider the
actual type of mutation (and not just which gene was
mutated), since in a particular gene, one type of muta-
tion may not be equivalent to another type. For example,
only specific EGFR mutations sensitize cells to EGFR
TKIs [140], different p53 mutations have markedly dif-
ferent effects on drug efficacy [141], and different KRAS
mutations drive activation of different downstream path-
ways [142].
Should drugs be approved based on phase II response?
As noted, survival is our gold standard outcome. Since
there are numerous examples of response not translating
into a survival advantage, many investigators regard
response as a suboptimal surrogate outcome. On the
other hand, above we outlined problems with RCCTs
with a survival endpoint in unselected patients, response
rate in single-agent phase II trials is a highly reliable pre-
dictor of eventual regulatory approval (p=0.005) [143],
response correlates very strongly with survival for both
chemotherapy [44,144] and targeted agents (p<0.0001)
[44], and the overwhelming majority of anticancer
agents approved by the FDA based on sustained
responses (without RCCTs) have withstood the test of
time [145]. The available data indicate that if a single
agent can induce a reasonable rate of sustained response
in pretreated patients from a defined population then it
should be approved for use, without the requirement for
RCCTs.
The probability of achieving a response with a
placebo-equivalent ineffective agent is very low (Table 3).
The larger the lesion that one measures, the more pre-
cise the measurement, and precision of measurement of
even small lesions can be improved by requiring meas-
urement of multiple (e.g., 4 or more) target lesions in a
given patient [113]. By reducing drug development costs
and by speeding access to effective new therapies,
approval of agents based on single-agent phase II data
Figure 5 Suggested trial structure for assessment of
combinations: Combination A+B would be compared to A
followed at progression by B and to B followed at progression by
A. Endpoints might include: 1) Time to progression on A+B vs time
to progression from the initiation of the first single agent until
completion of the second single agent; 2) A+B would be compared
to each of A alone or B alone with respect to time to progression
and maximum response; 3) Overall survival on the 3 arms; 4) Ability
of B to suppress emergence of specific resistant clones while on
A. 5) Of very high importance would be the development of
molecular signatures that predict unique benefit of A alone, B alone,
A+B combined, and the A→B/B→A sequences.
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crease the number of agents that can be tested using
available resources, and improve patient outcomes [4].
Approach to combining new agents with standard
therapies
Chemotherapy combinations are the standard of care as
first-line treatment for most malignancies. While the
data support single-agent response rates in pretreated
patients as a basis for drug approval, combinations are
problematic [146,147]. Outcome with a standard regi-
men may be quite variable. Hence, if one sees a better-
than-anticipated outcome when one adds a new agent to
a standard regimen, one cannot tell whether this is due
to variability in efficacy of the base regimen vs being due
to benefit from the new agent. To address this issue,
RCCT phase II trials have been proposed as a tool to
help select combinations worthy of further assessment
[146,147], but in addition to the problems already noted
above, RCCTs risk overstating the value of combina-
tions. For example, if drug A hits a target present in 25%
of patients and drug B hits a different target present in
20%, then a RCCT comparing A+B to A alone might
suggest that the combination is superior, with benefit in
45% of patients. A+B then becomes the new standard of
care. However, with A+B, all patients would potentially
be receiving one expensive, toxic drug that was not help-
ing them (since patients with target A would not benefit
from drug B, and patients with target B would not bene-
fit from drug A), and the 55% of patients with neither
target A nor target B would not benefit from either
agent. A better strategy would be to define who will bene-
fit from A, who will benefit from B, and to only treat pa-
tients with the drug(s) that would be expected to work in
them, rather than using a shotgun combination approach.
Furthermore, if the patient had both targets A and B,
the preferred option might be sequential therapy, since
giving single agents might be less toxic than combina-
tions, since higher doses of each drug might then be
feasible, and since higher doses may give enhanced effi-
cacy for some single agents [148]. With this sequential
approach, response rates and PFS on each individual
single agent might be lower than with A+B combined, but
there might not be any detrimental impact on survival,
provided patients did receive the agent(s) for which they
had targets. As an example, combination chemotherapy in
breast cancer increased response rates compared to
sequential single agents, but had no beneficial impact on
survival, and survival may even have been longer with
sequential therapy for some subgroups [149].
Potential synergism is one rationale for combinations,
but there are few clinical examples of true drug syner-
gism. There is also a rationale for combining targeted
agents that hit complementary pathways, but to datethere are few confirmed examples of combined targeted
agents being better than single agents, and toxicity is
often increased. Combinations might best be assessed
based on presence of demonstrable preclinical synergism
across a wide range of cell lines, or based on presence of
known targets for both agents, or based on a potential
for the second agent being able to block an alternate
growth pathway or resistance mechanism that might
protect against the first agent. It is important to have a
biologically-based hypothesis with respect to what one
expects to see with the combination, and that the trial
design is appropriate to test the hypothesis.
To assess combinations, we would suggest the following
approach: If one hypothesizes that drug B will be synergis-
tic with drug A, then randomize patients to A followed at
progression by B (the “A→ B” arm) vs B followed at pro-
gression by A (since there can be schedule-dependent syn-
ergism vs antagonism) [150] (the “B → A” arm) vs A
combined with B (the “A+B” arm). For potential study
endpoints see Figure 5. This would allow assessment of
whether A+B is better than either single agent alone, and
whether it is better than sequential therapy. It would also
be important to have baseline tissue to permit molecular
assessment of which patient subpopulations (if any) actu-
ally benefit from combination therapy.
In addition to improved PFS and survival, one would
also expect to see increased tumor regression with effect-
ive combinations. Even purportedly cytostatic agents such
as bevacizumab can significantly increase tumor response
rates when added to chemotherapy (Table 4) [151-155].
Table 4 Gain in response rate vs gain in survival for anticancer drugs approved by FDA 2002-2012
Drug Tumor type Gain in response rate p Gain in OS, months p
Oxaliplatin [156,171] Colorectal 48% vs 32% 0.006 5.6 <0.001
Pemetrexed [157] Mesothelioma 41.3% vs 16.7% <0.0001 2.8 0.02
Bevacizumab [152] Colorectal 44.8% vs 34.8% 0.004 4.7 <0.0001
Gemcitabine [158] Breast 41.4% vs 26.2% 0.0002 2.8 0.0489
Erlotinib [37] Pancreas 8.6% vs 8% NSa 0.33 0.038
Docetaxel [159] Gastric 37% vs 25% 0.01 1.9 <0.001
Topotecan [160] Cervix 27% vs 13% 0.004 2.9 0.017
Bevacizumab [153] Colorectal 22.7% vs 8.6% <0.0001 2.1 0.0011
Gemcitabine [161] Ovary 42.7% vs 30.9% 0.0016 0.7 0.83b
Bevacizumab [151] NSCLC 35% vs 15% <0.001 2 0.003
Docetaxel [162] Head and Neck 68% vs 54% 0.006 3.3 0.02
Lapatinib [163] Breast 22% vs 14% 0.09 NAc 0.72 b
Lapatinib [164] Breast 23.7% vs 13.9% 0.017 0.3 0.18 b
Temsirolimus [165] Renal 8.1% vs 4.8% NS 1.1 0.70 b
Ixabepilone [166,167] Breast 35% vs 14% <0.0001 1.8 0.19 b
Bevacizumab [154,155] Renal 31% vs 13% 0.0001 2.0 0.33 b
Lapatinib [168] Breast (Her-2/neu +ve) 28% vs 15% 0.021 1.0 0.11 b
Trastuzumab [169] Gastroesophageal 47% vs 35% 0.0017 2.7 0.0046
Cetuximab [170] Head and neck 36% vs 20% <0.001 2.7 0.04
a. NS: not significant.
b. PFS differed significantly.
c. NA: not available.
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2002 and 2012 [11], all except one that significantly
improved survival when added to standard therapy also sig-
nificantly improved response rates (Table 4) [37,151-171].
If one were anticipating additivity of A and B, it would
be important to use relevant biomarkers to select patients
with target for both agents. On the other hand, if one were
hypothesizing synergism (e.g., through concurrent blocking
of alternative signaling pathways), selection based on
anticipated sensitivity to single-agents might be less
important. For example, cisplatin radiosensitization may
be even greater in cisplatin-resistant cell lines than in
cisplatin-sensitive cell lines [172]. One might also require
few patients if there is synergism, since the combination
should give much better activity than either “A → B” or
“B→ A” if synergism is actually present.
If one hypothesizes that B will prevent emergence of a
resistant sub clone X during treatment with A (e.g., pre-
vention of emergence of a T790M-mutant clone during
treatment with an EGFR inhibitor [133]), then one might
use the “A → B” vs “B → A” vs “A+B” approach, but
with tumor biopsy at a set time point after starting A in
each of the 3 arms to assess ability of B to prevent emer-
gence of sub clone X, as well as to identify other sub
clones that might preferentially appear in the presenceof B. For example, while emergence of T790M-mutant
sub clones are one potential mechanism of acquired
resistance of EGFR-mutant NSCLC to EGFR TKIs,
emergence of resistant sub clones with c-Met amplifica-
tion may also occur [173].
Where one hypothesizes that B will be effective against
a clone X that is resistant to A, one can also use an
approach that is somewhat analogous to early studies in
which resistance modulators were added to standard
chemotherapy at the time of progression on chemother-
apy [174-178]. Here, one would initiate treatment with
A and would repeat a tumor biopsy once the tumor
stopped shrinking with A or began to grow. Patients
positive for X at that point might then be randomized to
B alone vs continuing A and adding B to assess tumor
regression and time to progression after initiation of B.
One would continue A in one arm since A might have
caused regression of a rapidly growing dominant clone, Y,
permitting outgrowth of a more slowly growing sub clone
X that is potentially sensitive to B, but if A is stopped, then
the original Y clone might grow back rapidly and lead to
progression on B alone. Such “flare” responses have been
documented for patients who had responded to a targeted
therapy and who had then had the targeted therapy
stopped at tumor progression [179].
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While RCCTs have contributed to modest progress, they
have also been inefficient, wasteful, and potentially mis-
leading. We cannot sustain the huge costs (in dollars
and in life-years lost) of our current approaches. We
need to change clinical trial designs to reflect the fact
that sensitizing mutations may be present in only a mi-
nority of patients with a given malignancy, we must put
a very high premium on obtaining tissue from clinical
trial patients, we should grant approval to single agents
that achieve high rates of sustained response in defined
groups of pretreated patients, and we must rethink how
we approach trials of drug combinations. The primary
endpoint of clinical trials needs to shift from the ques-
tion “Is the therapy of benefit overall to the group” to
the question “Who (if anyone) benefits?”
In summary, specific suggestions include the following:
1. A very high premium must be placed on tissue
acquisition for patients participating in trials of new
agents.
2. Do not do RCCTs in unselected patients unless
the drug target is known to be present in most
patients.
3. Do not use RCCTs in unselected patients to compare
2 agents with differing mechanisms of action.
4. For chemotherapy agents, we need to define the
molecular characteristics of sensitive tumors.
5. Response is generally a more efficient endpoint than
survival for discovering predictive biomarkers, and
progression-free survival is also more efficient than
overall survival.
6. To increase measurement precision, measure larger
tumors or else measure multiple smaller lesions.
7. Available data suggest that in searching for predictive
biomarkers, the proportion of patients who will be
biomarker-positive will generally be approximately
twice the size of the proportion responding or
approximately 5-10% less than the proportion of
patients achieving >10% reduction in tumor diameter.
8. Continuously variable (or graded) biomarkers are
generally less helpful in guiding therapy choices than
dichotomous biomarkers (present vs absent), unless
there is a marked nonlinear relationship between
biomarker expression and drug benefit (as with
estrogen receptors in breast cancer).
9. If using continuously variable biomarkers
that have a linear relationship with drug benefit:
a. Devise models that permit estimate of an
individual degree of benefit for a given patient.
b. Do not use arbitrary cut points to divide patients
into high-risk vs low-risk groups.
10. Archival tissue may be used for biomarkers in
those without prior response to a targeted therapy.11. A fresh biopsy should be done for biomarkers
in patients with prior response to a targeted therapy.
12. While reliability of FFPE methodologies may be
improving, carefully processed fresh biopsies may
improve reliability of gene expression arrays and of
some immunohistochemistry assessments.
13. Using biomarkers to select patients can markedly
reduce required RCCT patient numbers and costs.
14. For uncommon malignancies with few driving
mutations, current phase II methods may be
appropriate.
15. For phase II trials in common malignancies with
many potential driving mutations, either:
a. Select patients based on specific molecular
characteristics, or
b. Markedly increase trial size to ensure capture of
multiple subgroups, with suspension of accrual of
individual subgroups if no activity is seen in the
first few patients in that subgroup.16. If using an overall survival endpoint, collect detailed
information following discontinuation of study
therapy, including response to subsequent
interventions.
17. Approve drugs for marketing without RCCTs if
single-agent treatment gives a high rate of sustained
responses in heavily pretreated patients from a
defined population.
18. In assessing new combinations:
a. Do not abandon a new drug based solely on a
negative RCCT of a combination.
b. Use strategies that test whether the
combination is actually better than sequential
single agents.
c. Formulate a biologically based hypothesis as to
what you expect to see with the combination.
d. Use a trial design that is appropriate to test
your hypothesis.
e. If hypothesizing additivity or synergism:
i. Obtain baseline tissues to permit later
identification of sensitive subgroups
ii. Randomize to A followed by B (A→ B) vs B
followed by A (B → A) vs A+B
iii. Assess whether A+B is better than A → B and
B → A with respect to:
1. Time to failure on last of the sequential
drugs vs time to failure on A+B
2. Best response on either of the sequential
drugs vs best response on A+B
f. If hypothesizing that B will prevent outgrowth
of sub clone X that is resistant to A:
i. Obtain baseline tissue
ii. Randomize to A → B vs B → A vs A+B
iii. Assess total time to failure from start of
therapy to last therapy on each arm
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factors) in biopsies done at the time of
tumor progression on A on any arm, or at a
set time point after starting A on any arm.
g. If hypothesizing that B will be effective against
sub clone X that is resistant to A:
i. Obtain baseline tissue and initiate treatment
with A
ii. In patients with tumor regression on A:
1. Repeat biopsies when the tumor stopped
shrinking or started growing on A
2. If positive for X, randomize to B alone vs
continuing A and adding B
3. Assess response/further tumor regression with B
4. Assess time to progression after initiation of B.Abbreviations
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